Nevertheless, the present findings argue that a mechanism-based strategy involving concomitant cIAP1 and proteasome antagonism warrants attention in MM, particularly in the setting of Btz refractoriness or other forms of drug resistance (e.g., microenvironmental). This evidence concerns the gene BIRC2 and Miyoshi myopathy.